More on NVS
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $140.92 |
|
|||
| Open | $140.87 | ||||
| 52 Wk High | $89.15 | ||||
| 52 Wk Low | $69.84 | ||||
| Day High | $141.15 | ||||
| Day Low | $139.60 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 2,247,930 | ||||
- EMA panel backs Novartis Cosentyx for rheumatic condition in EU
- Novartis halts ALS drug development after mid-stage trial fails
- Selloff in this biotech stock is overdone – Mizuho
- Novartis (NOVN:SW) (NVS) PT Lowered to CHF105 at Berenberg
- Big Pharma Setbacks Create a New Wave of Rebound Plays
- Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
- Artisan Partners calls for Novartis board changes amid trial, acquisition failures
- Artisan Partners calls for board shake-up at Novartis after drug trial setbacks - Reuters
- HSBC Upgrades Novartis (NVS) to Hold
- HSBC Upgrades Novartis (NOVN:SW) (NVS) to Hold
Entities mentioned with NVS
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Earnings | View Related Stories »
- Twitter | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- JPMorgan | View Related Stories »
- Show More...
